Paradigm Biopharma - Disease modifying properties in iPPS Phase II
Paradigm reported favourable quantitative MRI data from the six-month analysis of the Phase II trial (PARA OA 008) evaluating a single six-week...
455 Views
Paradigm Biopharmaceuticals (PAR AU): Positive Result from Phase 2 Trial; Satisfactory Cash Position
Phase 2 trial shows that iPPS treats osteoarthritis symptoms as well as preserves/regenerates joint tissues, potentially leading to greater...
548 Views
Paradigm Biopharma - Durable responses observed for kOA
Paradigm has announced positive day-365 data from its Phase II trial (PARA_OA_008) assessing injectable pentosan polysulfate (iPPS) as a...
395 Views
Paradigm Biopharma - Progressing toward key near-term objectives
Paradigm has shared its June 2023 quarterly update. In Q423, net cash outflow from operating activities was A$17.1m (up from A$10.3m in Q323) or...
377 Views
Paradigm Biopharma - Pivotal Phase III progressing as planned
Paradigm has announced the completion of patient recruitment for stage one (dose selection) of its pivotal Phase III trial, PARA_OA_002, a...
481 Views